Latest News From BioPharmaChem
04 August, 2015
Irish manufacturing sector growth rebounded from a 16-month low in July as the weak euro boosted exports, a survey showed on Tuesday. The Investec Manufacturing Purchasing Managers’ Index rose to 56.7 in July from 54.6 in June.
06 August, 2015
Drugmaker Shire is seeking to buy Baxalta, a company spun-off by Baxter International, for $30 billion (€27.35 billion) to forge the leading global specialist in rare diseases.
07 August, 2015
Dublin-based Jazz Pharmaceuticals said revenues rose 15 per cent in the second quarter of the year as sales of its Xyrem product increased. The company reaffirmed financial guidance for 2015, which puts revenue in the projected range of $1.31 billion to $1.37 billion
11 August, 2015
Dublin-based drugmaker Mallinckrodt said Monday it would buy immunotherapy company Therakos in a deal valued at about $1.33 billion, its second major acquisition this year aimed at strengthening its hospital offerings.
13 August, 2015
There was a 33% increase in the number of professional job opportunities (12,887) when compared with the same month last year (9,699) according to the July 2015 Morgan McKinley Irish Employment Monitor which has been released today.
14 August, 2015
Goodbody Stockbrokers have today upgraded their economic growth forecasts, and now expect GDP growth of 5.5% in 2015 (previously 4.3%), with 4% expected for both 2016 and 2017.
24 August, 2015
Novartis has agreed to buy all remaining rights to Ofatumumab from Britain’s GlaxoSmithKline for up to $1 billion, boosting the Swiss drugmaker’s stable of multiple sclerosis (MS) treatments.
25 August, 2015
Biotechnology company Amgen, which yesterday unveiled its €260m facility in Dún Laoghaire, has launched two science education courses aimed at reaching more than 53,000 students and hundreds of teachers.
27 August, 2015
Irish medical devices firm Mainstay Medical, which agreed a debt facility of up to $15 million (€13.1 million) earlier this week, has been awarded an additional US patent as it continues with moves to bring a new product to market.
31 August, 2015
Drugmaker Bristol-Myers Squibb said it would buy the worldwide rights to a mid-stage fibrosis drug from privately held Promedior for up to $1.25 billion.